337962-79-5

Upstream product

• 59892-44-3 1-benzyl-5-nitropyridin-2(1H)-one 
• 353257-42-8 1-benzyl-5-chloropyridin-2(1H)-one 
• 100-39-0 benzyl bromide 
• 5418-51-9 5-nitro-2-pyridone 

Downstream Products

• 337962-88-6 2-[1-(1-benzyl-6-oxo-1,6-dihydro-pyridin-3-ylcarbamoyl)-cyclopentylmethyl]-pentanoic acid benzyl ester 
• 906070-00-6 2-{1-[(1-benzyl-6-oxo-1,6-dihydro-pyridin-3-yl)-methyl-carbamoyl]-cyclopentylmethyl}-pentanoic acid benzyl ester 

Relevant academic research and scientific papers

Novel Heterocyclic Compounds as Bromodomain Inhibitors

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides

Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.

Phosphodiesterase inhibitors for the treatment of female sexual dysfunction

A method of treating a female suffering from femal sexual dysfunction (FSD), in particular femal sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual gen